Possis Medical
This article was originally published in The Gray Sheet
Executive Summary
Files 510(k) application with FDA for three expanded polytetrafluoroethylene (ePTFE) synthetic vascular grafts, the Minneapolis firm announces Dec. 8. Once approved, the ePTFE grafts will complement Possis' Perma-Seal silicon elastomer dialysis access graft, approved by FDA in September. No independent distributor has been named for either the Perma-Seal or the ePTFE grafts. Possis retained Salomon Smith Barney in January 1998 to explore selling the entire vascular graft business, but the firm says it will not decide the fate of the division until distributors for the current products have been signed
You may also be interested in...
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.